Call Us: 888-488-5750

Are Self-Funded Employers Leaving Rebate Dollars Behind?

Self-funded employers have long recognized the importance of rebates in managing healthcare costs. Pharmacy benefit rebates are typically part of financial planning, built into projections, and often used to offset premiums or reinvest in employee programs.

But there’s another side of rebates that too often goes unnoticed: medical benefit rebates.

The Overlooked Rebate Opportunity

While PBMs handle most pharmacy benefit rebates, some of the highest-cost drugs today are billed under the medical benefit. These include infused therapies, oncology treatments, and physician-administered drugs.

Here’s the problem: most self-funded employers don’t have the infrastructure to identify, capture, and process rebates tied to these claims. That means valuable dollars go uncollected, even though they belong to the employer’s plan.

Why It Matters for Employers

For self-funded plans, unclaimed rebates aren’t just lost dollars—they’re missed opportunities to:

  • Reinvest in employee wellness and preventive care programs
  • Offset employee premium contributions
  • Strengthen the employer’s overall benefits strategy
  • Improve cost-containment and forecasting accuracy

Every rebate dollar left on the table is a dollar that could have been used to improve financial sustainability and enhance the employee experience.

Strategic Rebate Management

This is where strategic rebate management comes in. At VativoRx, we help self-funded employers unlock the full value of rebates across both pharmacy and medical benefits—without disrupting existing PBM or specialty pharmacy relationships.

Our approach to medical rebate management includes:

  • Clean, compliant submissions to manufacturers
  • Visibility into both pharmacy and medical rebate performance
  • Audit-ready documentation to safeguard employer dollars
  • Non-disruptive integration with existing benefit structures

The result is straightforward: more rebate dollars flowing back to the plan, with less administrative burden.

Real Talk

In our conversations with self-funded employers, we’ve seen a consistent pattern: employers are focused on cost sustainability and employee health—but most have no idea how much rebate value is left uncollected on the medical side.

This gap represents one of the clearest opportunities for employers to stretch health plan dollars further, reinvest in their workforce, and strengthen their overall benefits strategy.

The Bottom Line

Self-funded employers can no longer afford to think of rebates as a pharmacy-only solution. With specialty costs rising, the medical benefit rebate opportunity is too significant to ignore.

📩 Ready to capture every rebate dollar available to your plan?
Let’s talk about how VativoRx can help your organization build a smarter, more strategic rebate program. Contact us here.

Pharma Tariffs and Specialty Drug Cost Management: What Health Plans and TPAs Should Be Watching

On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority underlying longstanding tariffs on steel and aluminum. The headline rate is 100%. But for health plans and TPAs managing specialty drug costs, that number requires context before it becomes useful for strategic rebate management and financial planning.

Read More »

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »